بِسْمِ اللَّـهِ الرَّحْمَـٰنِ الرَّحِيمِ الَّذِي خَلَقَنِي فَهُوَ يَهْدِينِ وَالَّذِي هُوَ يُطْعِمُنِي وَيَسْقِينِ وَإِذَا مَرِضْتُ فَهُوَ يَشْفِينِ

What are the criteria needed for RSV vaccine?

Solved1.07K viewsImmunology
Avatar
0 Comments

فيه مندوب لشركة أدوية عدى علينا فى المستشفى بيقول ان الشركة هاتوفر الجرعة الوقائية الاولى مجانا و بعد كده باقى الجرعات هاتكون بمبلغ ٥ آلاف جنيه للجرعة الواحدة، و احنا اتعلمنا انه علاج النوع ده من الفيروسات بيكون supportive إلا فى حالات معينة

فهل فيه تحديث للمعلومة؟

Hossam Elgnainy Selected answer as best October 10, 2024

1 Answer

0
Hossam Elgnainy3.34K 4 Comments

The CDC Clinical Guidance for RSV Immunizations and Vaccines is very informative regarding your question.

https://www.cdc.gov/rsv/hcp/vaccine-clinical-guidance/index.html

You can also check the Canadian guidelines

https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/respiratory-syncytial-virus.html

While we don’t know the name of the vaccine you are talking about, we can not provide a specific answer.

Hossam Elgnainy Selected answer as best October 10, 2024
Avatar
Yasmin Abd Allah commented

Thank you for reply
I have asked about SYNAGIS 50& 100 mg/ ml (Palivizumab)
Hossam Elgnainy commented

Palivizumab is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in children at high risk of RSV disease.
.
High risk for RSV:
1. Children (≤2 yr) with bronchopulmonary dysplasia
2. Infants with a history of premature birth (≤35 weeks gestational age)
3. Children (≤2 yr) with hemodynamically significant congenital heart disease
Hossam Elgnainy commented

According to AAP, Nirsevimab is preferred over palivizumab because of its efficacy, duration, and convenience.
https://publications.aap.org/redbook/resources/25379/AAP-Recommendations-for-the-Prevention-of-RSV
You are viewing 1 out of 1 answers, click here to view all answers.